ArticleBone research2019
NOTUM inhibition increases endocortical bone formation and bone strength.
Article in Bone research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Proteomic Biomarkers Associated with Low Bone Mineral Density: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Discovery of anthraquinones as potent Notum inhibitors for treating osteoporosis by integrating biochemical, phytochemical, computational, and experimental assays.Journal of pharmaceutical analysis · 2026Article
- Wnt16: a new potential therapeutic target for osteoporotic non-vertebral fracture treatment.Frontiers in aging · 2026Review
- Progress on novel compounds for the treatment of bone metabolism-related disorders: focus on osteoporosis and beyond.Frontiers in chemistry · 2026Review
- High-efficient discovering the potent anti-Notum agents from herbal medicines for combating glucocorticoid-induced osteoporosis.Acta pharmaceutica Sinica. B · 2025Article
- Notum as a Crucial Regulator of Matrix Integrity in Dentinogenesis.Journal of cellular physiology · 2025Article
- A comprehensive review and advanced biomolecule-based therapies for osteoporosis.Journal of advanced research · 2025Review
- Stress reduction through cortical bone thickening improves bone mechanical behavior in adult female Beclin-1Frontiers in bioengineering and biotechnology · 2024Article
- Designed switch from covalent to non-covalent inhibitors of carboxylesterase Notum activity.European journal of medicinal chemistry · 2023Article
- Skeletal phenotypes in secreted frizzled-related protein 4 gene knockout mice mimic skeletal architectural abnormalities in subjects with Pyle's disease from SFRP4 mutations.Bone research · 2023Article
- Large-scale synthesis of Notum inhibitor 1-(2,4-dichloro-3-(trifluoromethyl)-phenyl)-1RSC advances · 2022Article
- Structural Analysis and Development of Notum Fragment Screening Hits.ACS chemical neuroscience · 2022Article
- Probucol promotes osteoblasts differentiation and prevents osteoporosis development through reducing oxidative stress.Molecular medicine (Cambridge, Mass.) · 2022Article
- Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit.Journal of medicinal chemistry · 2022Article
- Article
- Sfrp4 and the Biology of Cortical Bone.Current osteoporosis reports · 2022Review
- Estradiol and RSPO3 regulate vertebral trabecular bone mass independent of each other.American journal of physiology. Endocrinology and metabolism · 2022Article
- Review
- Preparation, characterization, and osteogenic activity mechanism of casein phosphopeptide-calcium chelate.Frontiers in nutrition · 2022Article
- Insights into auto-RSC chemical biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The disability, mortality and costs caused by non-vertebral osteoporotic fractures are enormous. Existing osteoporosis therapies are highly effective at reducing vertebral but not non-vertebral fractures. Cortical bone is a major determinant of non-vertebral bone strength. To identify novel osteoporosis drug targets, we phenotyped cortical bone of 3 366 viable mouse strains with global knockouts of druggable genes. Cortical bone thickness was substantially elevated in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.